Chemotherapy for Elderly Patients Diagnosed With Localized HER2 Positive Breast Cancer
Status:
Withdrawn
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
There is major concern regarding chemotherapy related toxicity in the group of women older
than 65 years old diagnosed with human epidermal growth factor receptor 2 (HER2) positive
breast cancer (BC). Nevertheless, these patients are at a particularly high risk of breast
cancer recurrence and death. Of note, older patients may experience higher risk for
Trastuzumabe related cardiotoxicity, especially when this agent is combined with an
anthracycline.
Recent studies have shown extremely favourable outcomes in early HER2+ BC patients treated
with a combination of paclitaxel and trastuzumab, omitting anthracyclines from treatment.
Investigators sought to investigate safety and outcome data on a cohort of elderly patients
treated with weekly paclitaxel combined with carboplatin and trastuzumab.